Second Line Capital LLC Buys Shares of 131,122 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Second Line Capital LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 131,122 shares of the company's stock, valued at approximately $1,529,000. Second Line Capital LLC owned about 0.13% of Intellia Therapeutics as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Sterling Capital Management LLC increased its position in shares of Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock valued at $37,000 after buying an additional 2,867 shares during the period. Whipplewood Advisors LLC purchased a new position in shares of Intellia Therapeutics during the fourth quarter valued at about $40,000. Resona Asset Management Co. Ltd. purchased a new position in shares of Intellia Therapeutics during the fourth quarter valued at about $43,000. Jones Financial Companies Lllp increased its position in shares of Intellia Therapeutics by 140.9% during the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock valued at $45,000 after buying an additional 2,280 shares during the period. Finally, Daiwa Securities Group Inc. increased its position in shares of Intellia Therapeutics by 80.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock valued at $60,000 after buying an additional 2,299 shares during the period. 88.77% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Chardan Capital restated a "buy" rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a report on Friday, May 9th. Wedbush reaffirmed a "neutral" rating and issued a $10.00 price target on shares of Intellia Therapeutics in a research report on Monday. Wells Fargo & Company lowered their price target on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Truist Financial cut their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and set a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $36.90.

Intellia Therapeutics Trading Up 6.7%

Shares of NASDAQ NTLA traded up $0.61 during trading hours on Tuesday, reaching $9.67. The stock had a trading volume of 5,212,431 shares, compared to its average volume of 2,540,429. The firm has a 50-day moving average of $7.98 and a 200-day moving average of $10.68. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -1.78 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. The firm's revenue was down 42.6% compared to the same quarter last year. During the same quarter last year, the business posted ($1.12) EPS. On average, equities analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.